Key Developments: Synta Pharmaceuticals Corp (SNTA.OQ)

SNTA.OQ on NASDAQ Stock Exchange Global Market

2.96USD
31 Oct 2014
Price Change (% chg)

$-0.05 (-1.66%)
Prev Close
$3.01
Open
$3.08
Day's High
$3.11
Day's Low
$2.95
Volume
244,901
Avg. Vol
408,689
52-wk High
$7.22
52-wk Low
$2.62

Search Stocks

Latest Key Developments (Source: Significant Developments)

Synta Pharmaceuticals Corp announces initiation of I-SPY 2 TRIAL of Ganetespib in breast cancer
Wednesday, 29 Oct 2014 07:00am EDT 

Synta Pharmaceuticals Corp:Announces initiation of I-SPY 2 TRIAL ( I nvestigation of S erial Studies to P redict Y T herapeutic R esponse with I maging A nd mo L ecular Analysis 2 ) arm evaluating ganetespib company's Hsp90 inhibitor, as neoadjuvant therapy for patients with breast cancer.I-SPY 2 is standing Phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in neoadjuvant setting.I-SPY 2 is conducted by consortium that brings together Food and Drug Administration (FDA), National Cancer Institute (NCI), pharmaceutical companies, academic medical centers, and patient advocacy groups under umbrella.The I-SPY 2 TRIAL employs adaptive trial design to match experimental therapies with patients.Genetic or biological markers from individual patients' tumors are used to screen promising new treatments, identifying which treatments are effective in specific patient subgroups.Regimens that have high Bayesian predictive probability of showing superiority in a 300 patient phase 3 confirmatory trial in at least one of 10 predefined signatures may "graduate" from I-SPY 2.Regimen can graduate early and at any time after having 60 patients assigned to it, and exits the trial after maximum of 120 patients.  Full Article

Synta Pharmaceuticals Corp names Anne Whitaker as President and Chief Executive Officer
Wednesday, 6 Aug 2014 07:01am EDT 

Synta Pharmaceuticals Corp:Anne Whitaker will join the company as President, Chief Executive Officer and a member of the company's Board of Directors effective Sept. 2.  Full Article

Synta Pharmaceuticals Corp sells $5 mln shares
Monday, 14 Apr 2014 08:00am EDT 

Synta Pharmaceuticals Corp:Entry into subscription agreement with an entity affiliated with Bruce Kovner.Agreement to sell 1,250,000 shares of its common stock at price of $4.01 per share.Proceeds expected to be about $5.0 mln.Net proceeds used to research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for general corporate purposes.  Full Article

Synta Pharmaceuticals Corp announces positive interim results from ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer
Thursday, 20 Mar 2014 05:45am EDT 

Synta Pharmaceuticals Corp:Presentation of interim results from ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, administered as monotherapy for treatment of metastatic breast cancer.ENCHANT-1 trial was designed to evaluate ganetespib single agent activity in metastatic breast cancer and identify potential predictive biomarkers.Target enrollment is 35 patients in three cohorts, which include HER2+ breast cancer, triple-negative breast cancer (TNBC), and, recently added andrecruiting, ER/PR-positive patients previously untreated for locally advanced or metastatic disease.Goal of trial design is to obtain initial evidence of clinical activity signal with single-agent ganetespib administered for up to 12 weeks.Continuation of ganetespib as a single agent or in combination with paclitaxel after initial assessment is at investigator discretion.  Full Article

Synta Pharmaceuticals Corp announces executive management changes
Monday, 3 Mar 2014 04:01pm EST 

Synta Pharmaceuticals Corp:Announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed Executive Committee of the Board.Committee will serve as the principal executive body for the Company until such time as a Chief Executive Officer is named.  Full Article

Synta Pharmaceuticals Corp announces positive interim results from the ENCHANT-1 Trial
Thursday, 12 Dec 2013 08:45am EST 

Synta Pharmaceuticals Corp:Says the presentation of results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib.Says results are being presented during a poster session at the 2013 San Antonio Breast Cancer Symposium in San Antonio, Texas.Says ENCHANT-1 trial is designed to evaluate the efficacy and safety of ganetespib monotherapy for treatment of HER2+ (Cohort A) or triple-negative (Cohort B) breast cancer (TNBC) patients previously untreated for locally advanced or metastatic disease.Says third cohort was recently added to evaluate ganetespib in ER/PR+, HER2- (HER2-negative) patients.  Full Article

Synta Pharmaceuticals Corp Closes Public Offering Of Common Stock
Monday, 18 Nov 2013 10:10am EST 

Synta Pharmaceuticals Corp. announced that the closing of its underwritten public offering of 16,100,000 shares of common stock, including 2,100,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $3.75 per share. Gross proceeds to Synta are approximately $60.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. Jefferies LLC acted as the sole book-running manager for the offering, and JMP Securities, Brean Capital, LLC and Roth Capital Partners acted as co-managers for the offering.  Full Article

Synta Pharmaceuticals Corp Prices Public Offering of Common Stock
Wednesday, 13 Nov 2013 09:00am EST 

Synta Pharmaceuticals Corp. announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $3.75 per share. Gross proceeds to Synta are expected to be approximately $52.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The offering is expected to close on or about November 18, 2013, subject to satisfaction of customary closing conditions. Synta has granted the underwriters a thirty (30) day option to purchase up to 2,100,000 additional shares. Jefferies LLC is acting as the sole book-running manager for the offering, and JMP Securities, Brean Capital, LLC and Roth Capital Partners are acting as co-managers for the offering.  Full Article

Synta Pharmaceuticals Corp Announces Proposed Public Offering of Common Stock
Tuesday, 12 Nov 2013 04:01pm EST 

Synta Pharmaceuticals Corp announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC is acting as the sole book-running manager for the proposed offering.  Full Article

Synta Pharmaceuticals Corp Shares Fall After Cancer Drug Shows Less Benefit-Reuters
Monday, 28 Oct 2013 12:19pm EDT 

Reuters reported that shares of Synta Pharmaceuticals Corp fell on Monday after updated data from a mid-stage lung cancer trial showed that its drug had less clinical benefit than previously reported. The drug, ganetespib, reduced the chance of death in patients by 25%, lower than the 39% the company announced in June from an earlier analysis. The company presented the latest data over the weekend. The mid-stage study, Galaxy-1, was intended to identify patients most likely to benefit from the use of the drug. These patients have been enrolled in a late-stage study, testing ganetespib plus a chemotherapy drug, docetaxel, in those with advanced non-small cell lung cancer who had failed prior treatment. The company would limit recruitment from two Eastern European countries for the late-stage study. The company is also considering increasing enrollment in the trial to 700 or 800 patients, from the 500 patients it planned. Ganetespib is designed to inhibit a protein, which activates other proteins that play a role in the growth of cancer cells. The drug is also being tested in three studies as a treatment for breast cancer.  Full Article

Search Stocks